PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Novartis’ rare renal disease candidate shows promise in phase II

Interim analysis results for Novartis’ rare renal disease candidate iptacopan proved promising in a phase II study of the investigational drug.

The oral investigational candidate was evaluated as a treatment for C3 glomerulopathy (C3G) – a rare renal disease affecting young patients which carries a poor prognosis with a high unmet medical need.

The data, presented at the virtual American Society of Nephrology (ASN) 2020 annual meeting, from the phase II study of iptacopan showed that after 12 weeks, the drug significantly reduced proteinuria by 49% compared to baseline values in 12 patients with C3G.

“Proteinuria indicates the presence of inflammation in the kidney. Results from this study demonstrate that iptacopan significantly reduces proteinuria in patients with C3G,” said the Edwin Wong, lead study investigator, consultant nephrologist at the National Renal Complement Therapeutics Centre, Newcastle upon Tyne NHS Foundation Trust, Newcastle University.

“This data also highlights iptacopan’s ability to strongly and specifically inhibit the alternative complement pathway, targeting the underlying cause of this disease and potentially providing a much needed treatment option for C3G patients who have significant unmet needs,” he added.

In addition, iptacopan stabilised renal function as assessed by estimated glomerular filtration rate (eGFR) at week 12, and this effect was maintained in the seven patients that were treated for a total of six months after rolling over into the long-term expansion study.

The European Medicines Agency (EMA) has already granted Novartis’ drug a PRIME designation in C3G. The EMA has also granted an orphan drug designation for iptacopan in IgA nephropathy (IgAN).

Alongside C3G, iptacopan is in parallel development for a number of other renal conditions with complement system involvement where significant unmet needs still exist.

This includes IgAN, atypical haemolytic uremic syndrome and membranous nephropathy, as well as paroxysmal nocturnal haemoglobinuria (PNH).

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026